Gujarat inject Kerala Limited has announced its unaudited standalone financial results for the third quarter and nine months ended December 31, 2025. The Board of Directors approved these results during their meeting held on February 14, 2026, under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting and Regulatory Compliance

The Board meeting was conducted on Saturday, February 14, 2026, commencing at 3:00 PM and concluding at 3:35 PM. The meeting was held pursuant to Regulation 30 of the SEBI Listing Regulations, where directors approved the unaudited financial results and took on record the Limited Review Report issued by M/s. S. Mandawat & Co., the company's statutory auditors.

Financial Performance Overview

The company's quarterly and nine-month financial performance demonstrates significant revenue growth compared to the previous year, though with varying profit margins across different reporting periods.

Quarterly Results Analysis

For the third quarter ended December 31, 2025, Gujarat Inject Kerala Limited reported revenue from operations of ₹162.51 lakh, marking a substantial increase from ₹13.80 lakh in the corresponding quarter of the previous year. However, the net profit for the quarter decreased to ₹3.80 lakh compared to ₹6.75 lakh in Q3FY25. The company's total expenses for Q3FY26 stood at ₹171.32 lakh, while the profit before tax was ₹5.08 lakh with current tax expense of ₹1.28 lakh.

Nine-Month Performance

For the nine months ended December 31, 2025, the company achieved revenue from operations of ₹502.26 lakh, significantly higher than ₹19.64 lakh in the corresponding period of the previous year. Net profit for the nine-month period was ₹94.40 lakh compared to ₹101.72 lakh in the previous year.

Share Capital and Earnings Per Share

The company maintained consistent equity structure with paid-up equity share capital of ₹1,463.48 lakh and face value of ₹10.00 per share. Basic earnings per share from continuing operations for Q3FY26 was ₹0.03, compared to ₹0.05 in the corresponding quarter of the previous year.

Accounting Standards and Segment Information

The financial results were prepared in accordance with Indian Accounting Standards 34 "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013. The company operates in a single reportable segment as per Indian Accounting Standard 108 on "Operating Segment". The results were reviewed by the Audit Committee and subsequently approved by the Board of Directors, with statutory auditors conducting a limited review of the financial statements.

Gujarat inject (Kerala) Limited has announced a significant change in its board composition with the resignation of an Independent Director. The company communicated this development to the BSE on December 13, 2025, in compliance with regulatory requirements.

Director Resignation Details

Mrs. Reena Mahatma (DIN: 02846012) has resigned from her position as Non-Executive Independent Director of the company. The resignation became effective from the close of business hours on December 9, 2025. The formal resignation process was initiated through a resignation letter dated December 8, 2025, which the company received on December 9, 2025.

Reason for Departure

In her resignation letter, Mrs. Mahatma cited pre-occupation elsewhere and other personal commitments as the primary reasons for stepping down from her directorship. She confirmed that there were no other reasons beyond those stated for her resignation. The director also acknowledged that the company had cleared all her dues and confirmed she had no outstanding claims from the organization.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notification was made in accordance with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, which governs the disclosure requirements for changes in board composition.

Company Communication

The formal communication to BSE was signed by Murlish Ivshankar Annair, Whole-Time Director (DIN: 02243039), on behalf of Gujarat Inject (Kerala) Limited. The company's registered office is located in Vadodara, Gujarat, and it operates under CIN: L46309GJ1991PLC151872 with BSE scrip code 524238.